Tracking New Treatments for Newly Diagnosed Multiple Myeloma Patients

Recruiting · Phase 2 · Multiple Myeloma, Newly Diagnosed and related conditions · 9 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This clinical trial is looking at two different ways to treat newly diagnosed multiple myeloma. The main goal is to see which method can help patients achieve undetectable measurable residual disease in their bone marrow. Participants will either receive a combination of two medicines called elranatamab and daratumumab or undergo a procedure called autologous stem cell transplant followed by additional treatment with lenalidomide and daratumumab.

This is a Phase 2 trial, which means it is looking at how well the treatments work and how safe they are. About 100 participants will be involved, and the trial is regulated by the FDA.

Who can join

Adults aged 19 and older can join this study. It is open to both men and women who have been diagnosed with multiple myeloma within the last 12 months and have had some initial treatment. The trial team will check if each person meets all the requirements to participate.

Conditions

Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly placed into one of two groups. In the first group, participants will receive elranatamab and daratumumab in a series of doses over time. In the second group, participants will undergo the stem cell transplant followed by lenalidomide and daratumumab. If participants have measurable disease after initial treatment, they may receive additional treatments based on their results.